AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00082498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Group 1 will receive placebo.
Trial: NCT00003516
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Trial: NCT01184664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline + placebo patch
Trial: NCT01811706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally every 12 hours, for a 4 week period.
Trial: NCT02763033
Drug: Bob's Red Mill®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bone marrow transplant (BMT) diet + potato-based starch
Trial: NCT03435003
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
Trial: NCT02087748
Drug: 1% diclofenac sodium gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
Trial: NCT02087748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel 4gm applied topically Q6 hour for 48 hours
Trial: NCT01103245
Drug: Spironolactone (SPL 25)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 25mg daily
Trial: NCT00377793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01103245
Drug: Spironolactone 50 mg (SPL 50)
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg daily
Trial: NCT00955487
Drug: Inhaled Nitric Oxide (iNO)
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
Trial: NCT02692742
Drug: Myelo001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Trial: NCT02692742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Trial: NCT04181255
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
Trial: NCT02665065
Drug: Iomab-B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02665065
Drug: Conventional Care
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02827305
Drug: Gotukola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of mouthwash to be rinsed for duration of 60 seconds
Trial: NCT03882892
Drug: Atovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
Trial: NCT03882892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matched to ezetimibe
Trial: NCT01405924
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
Trial: NCT00154791
Drug: 5-FU/LV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01557023
Drug: barrier methods
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02506257
Drug: 0.04% PHMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Trial: NCT02506257
Drug: 0.06% PHMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Trial: NCT02506257
Drug: 0.08% PHMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Trial: NCT01924767
Drug: BI 10773 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po taken fasting with 240 mL water
Trial: NCT04466904
Drug: IBI362
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated by subcutaneous injection
Trial: NCT04466904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated by subcutaneous injection
Trial: NCT03479736
Drug: Other Antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
Trial: NCT00653341
Drug: NPH human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00101686
Drug: Oral Capecitabine with Irinotecan
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
Trial: NCT00348439
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
Trial: NCT01664910
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01436071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder delivered by Novel Dry Powder Inhaler
Trial: NCT00584168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
Trial: NCT02950948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
Trial: NCT00973453
Drug: PURETHAL Mites 20,000 AUeq/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Trial: NCT00973453
Drug: PURETHAL Mites 20,000 AUeq/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Trial: NCT00973453
Drug: PURETHAL Mites 20,000 AUeq/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Trial: NCT03460756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01054456
Drug: palonesetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose administered intravenously 30 minutes pre-chemotherapy
Trial: NCT02874430
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04438694
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care drugs administered as per Cairo University ICU protocol
Trial: NCT03030248
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
Trial: NCT00752050
Drug: Preservative-free Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Trial: NCT00750724
Drug: normal saline,2 ml., intraarticular weekly for 5 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03018236
Drug: Alcohol N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
Trial: NCT03522467
Drug: MRCP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
Trial: NCT01135680
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
Trial: NCT03018236
Drug: Alcohol Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
Trial: NCT03018236
Drug: Cocaine N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
Trial: NCT01135680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
Trial: NCT00889499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHCL 0,9%
Trial: NCT02498288
Drug: Isotretinoin: Reference Medication 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Trial: NCT02498288
Drug: Isotretinoin: Reference Medication 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Trial: NCT03146065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Placebo to different doses of PF-06730512
Trial: NCT01135680
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
Trial: NCT02498288
Drug: Isotretinoin: Test Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
Trial: NCT03563066
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
Trial: NCT01623115
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Trial: NCT01623115
Drug: Lipid Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Trial: NCT00006252
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
Trial: NCT02656420
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as comparison to broccoli sprout-derived beverages
Trial: NCT03873766
Drug: Intrapleural Medications
RxNorm normalized name: INTRAPLEURAL MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
Trial: NCT02625792
Drug: Endo-Clot(TM)
RxNorm normalized name: 2-acetoxy-1, 8-cineole, (+)-endo-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
Trial: NCT01599000
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed-dose tablet, six doses over three days, according to weight group
Trial: NCT05713773
Drug: coated beads glucose (8 g) and caffeine anhydrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Trial: NCT02318563
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching oral solution containing no cannabidiol
Trial: NCT03788174
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Trial: NCT02336607
Drug: Felodipine tablet (Plendil)+Hydrochlorothiazide
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled.
Trial: NCT05713773
Drug: coated beads glucose (8 g)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Trial: NCT01180335
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles FEC followed by 4 cycles docetaxel
Trial: NCT01527968
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
Trial: NCT00903227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff of inhaled Placebo twice a day
Trial: NCT00903227
Drug: Placebo intranasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intranasal spray 2 squirts each nostril once a day
Trial: NCT02709655
Drug: Fluoxetine 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Trial: NCT01600729
Drug: No Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention.
Trial: NCT03170726
Drug: arveles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative and postoperative pain values between these three groups will be compared.
Trial: NCT03170726
Drug: intrafen 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
Trial: NCT00433199
Drug: Testosterone (T) Gel 1.62%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
Trial: NCT00433199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control
Trial: NCT01920594
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
Trial: NCT01920594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
Trial: NCT00679588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Trial: NCT01454596
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
Trial: NCT02434744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed in combination
Trial: NCT02869022
Drug: Custodiol-N
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Trial: NCT02869022
Drug: Custodiol
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
Trial: NCT02394314
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0382 administered subcutaneously
Trial: NCT01170962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet, Oral, 0mg, Once daily, 24 weeks
Trial: NCT03887650
Drug: Liposomal Bupivicaine 1.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
Trial: NCT02394314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT00488488
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Trial: NCT03367728
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP and Rectus Sheath Block Injections of Normal Saline
Trial: NCT03111238
Drug: REX-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REX-001 is administered through an intra-arterial catheter.
Trial: NCT03111238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered through an intra-arterial catheter.
Trial: NCT00871767
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tablet (Test formulation)
Trial: NCT00871767
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tablet (Reference formulation)
Trial: NCT00871767
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet (Test formulation)
Trial: NCT00871767
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (2 x 50 mg tablet (Reference Formulation)
Trial: NCT02872116
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days